Benzinga | Aug 17, 2021 05:29AM EDT

Piper Sandler Initiates Coverage On Cytek Biosciences with Overweight Rating, Announces Price Target of $28

Piper Sandler analyst Steven Marotta initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $28.